Dr. Tamer Elhossieny, Vice Chairman of the Egyptian Drug Authority (EDA), received the regional team of Johnson & Johnson, headed by Mr. Ismail Al Ghussein, Regional Director of Corporate and Media Affairs, to discuss avenues of cooperation and partnership between both sides, as well as the regulatory and operational developments related to the company’s activities within the Arab Republic of Egypt.
During the meeting, Dr. Tamer Elhossieny emphasized the Authority’s continued efforts to provide all forms of regulatory and technical support to companies operating in the pharmaceutical sector, in a manner that contributes to enhancing the pharmaceutical investment climate and achieving a balance between local market needs and the interests of Egyptian patients, while also supporting the stability of the national industry.
He also noted that the Authority places special emphasis on strengthening partnerships with global companies operating in the Egyptian market through the development of the regulatory environment and the facilitation of procedures. This approach encourages the attraction of further investments and supports local manufacturing and technology transfer plans, which in turn contributes to improving the efficiency of the pharmaceutical system, ensuring the availability of pharmaceutical products with quality and sustainability, and enhancing the competitiveness of the Egyptian pharmaceutical sector regionally and internationally.
For their part, representatives of Johnson & Johnson praised the regulatory developments taking place in Egypt’s pharmaceutical sector, as well as the efforts exerted by the Egyptian Drug Authority to support the pharmaceutical investment climate and facilitate regulatory procedures. They affirmed the company’s commitment to strengthening its partnerships with the Authority and expanding areas of cooperation in a manner that supports local manufacturing plans, enhances supply chain efficiency, and ensures the sustainable availability of pharmaceutical products in the Egyptian market in accordance with the highest international quality standards.
Both sides discussed mechanisms for coordination to support technical personnel, contributing to the achievement of the company’s strategic objectives and supporting the stability of industrial operations in line with local market requirements.
This comes within the framework of the Egyptian Drug Authority’s commitment to supporting the pharmaceutical industry and strengthening strategic partnerships with major global companies operating in the Egyptian market, in a way that contributes to developing the pharmaceutical system and enhancing the availability of pharmaceutical products with high quality and efficiency.